Table 3:
Maximum reactogenicity within 8 days of vaccination
| Group 1 (n=10) | Group 2 (n=10) | Group 3 (n=10) | Placebo* (n=6) | |
|---|---|---|---|---|
| Local symptoms | ||||
| Pain/Tenderness | ||||
| Any | 10 (100%) | 8 (80%) | 10 (100%) | 2 (33%) |
| Grade 3 | 0 | 1 (10%) | 1 (10%) | 0 |
| Erythema | ||||
| Any | 0 | 1 (10%) | 0 | 0 |
| Systemic symptoms | ||||
| Fatigue | ||||
| Any | 10 (100%) | 8 (80%) | 8 (80%) | 4 (67%) |
| Grade 3 | 1 (10%) | 2 (20%) | 2 (20%) | 0 |
| Myalgia | ||||
| Any | 8 (80%) | 7 (70%) | 7 (70%) | 2 (33%) |
| Grade 3 | 1 (10%) | 0 | 2 (20%) | 0 |
| Headache | ||||
| Any | 8 (80%) | 7 (70%) | 5 (50%) | 2 (33%) |
| Grade 3 | 0 | 1 (10%) | 1 (10%) | 0 |
| Chills | ||||
| Any | 7 (70%) | 4 (40%) | 5 (50%) | 2 (33%) |
| Grade 3 | 0 | 1 (10%) | 2 (20%) | 0 |
| Nausea | ||||
| Any | 7 (70%) | 3 (30%) | 1 (10%) | 1 (17%) |
| Grade 3 | 0 | 1 (10%) | 1 (10%) | 0 |
| Pyrexia | ||||
| Any | 4 (40%) | 2 (20%) | 1 (10%) | 0 |
*
Endpoints for placebo recipients from Groups 1–3 were pooled into a single “Placebo” group.